ALK and non-small cell lung carcinoma: Lorlatinib showed remarkable efficacy in the CROWN study, achieving an mPFS of 33.3 months compared to 9.3 months with crizotinib (hazard ratio [HR]: 0.28, 95% CI: 0.19–0.41), highlighting its significant advantage in delaying disease progression in patients with ALK-positive NSCLC, while maintaining a manageable safety profile [24].